for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oramed Pharmaceuticals, Inc.

ORMP.OQ

Latest Trade

3.95USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.33

 - 

6.05

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.95
Open
--
Volume
--
3M AVG Volume
2.87
Today's High
--
Today's Low
--
52 Week High
6.05
52 Week Low
2.33
Shares Out (MIL)
23.53
Market Cap (MIL)
93.40
Forward P/E
-6.88
Dividend (Yield %)
--

Latest Developments

More

Oramed Reports Positive End Of Phase 2 Meeting With The FDA For Oral Insulin

Oramed Pharmaceuticals Reports Quarterly Loss Per Share Of $0.10

Oramed Pharmaceuticals Oral Insulin FDA End-Of-Phase 2 Meeting Expected This Quarter

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Oramed Pharmaceuticals, Inc.

Oramed Pharmaceuticals Inc. is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which is a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. The Company's other product is ORMD-0901, an orally ingestible GLP-1 capsule.

Industry

Biotechnology & Drugs

Contact Info

1185 Avenue of the Americas Ste 228

NEW YORK, NY

10036-2601

United States

+1.646.8441164

http://oramed.com

Executive Leadership

Kevin L. Rakin

Chairman of the Board, Independent Director

Nadav Kidron

President, Chief Executive Officer, Director

Avi Gabay

Chief Financial Officer, Treasurer, Secretary

Joshua Hexter

Chief Operating and Business Officer

Miriam Kidron

Chief Scientific Officer, Director

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.790

2018

-0.860

2019

-0.820

2020(E)

-0.545
Price To Earnings (TTM)
--
Price To Sales (TTM)
34.47
Price To Book (MRQ)
2.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-29.08
Return on Equity (TTM)
-25.83

Latest News

Latest News

BRIEF-Oramed Pharmaceuticals Reports Quarterly Loss Per Share Of $0.10

* ORAMED PHARMACEUTICALS INC QUARTERLY REVENUES $681,000 VERSUS $682,000 Source text: [https://bit.ly/3iHdMF9] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Oramed Patent In Canada Allowed For Oral Delivery Of Proteins

* ORAMED PATENT IN CANADA ALLOWED FOR ORAL DELIVERY OF PROTEINS Source text for Eikon: Further company coverage:

BRIEF-Oramed Pharmaceuticals Oral Insulin FDA End-Of-Phase 2 Meeting Expected This Quarter

* ORAMED PHARMACEUTICALS INC - ORAL INSULIN FDA END-OF-PHASE 2 MEETING EXPECTED THIS QUARTER

BRIEF-Oramed Receives Positive Feedback From End-Of-Phase 2 Oral Insulin Cmc Meeting With FDA

* ORAMED RECEIVES POSITIVE FEEDBACK FROM END-OF-PHASE 2 ORAL INSULIN CMC MEETING WITH FDA

BRIEF-Oramed Pharmaceuticals Prices Public Offering Of Stock For Proceeds Of $21 Mln

* ORAMED PHARMACEUTICALS INC. PRICES PUBLIC OFFERING OF COMMON STOCK FOR AGGREGATE PROCEEDS OF $21 MILLION

BRIEF-Oramed Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* ORAMED PHARMACEUTICALS INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Oramed Reports Positive Results In The Final Cohort Of Its Phase 2B Oral Insulin Trial

* ORAMED REPORTS POSITIVE RESULTS IN THE FINAL COHORT OF ITS PHASE 2B ORAL INSULIN TRIAL

BRIEF-Oramed Pharmaceuticals May Offer, Sell Additional Shares Of Common Stock Having Sales Price Of Not More Than $12.7 Million

* ORAMED PHARMACEUTICALS - MAY OFFER, SELL UNDER PROSPECTUS SUPPLEMENT ADDITIONAL SHARES OF COMMON STOCK HAVING SALES PRICE OF NOT MORE THAN $12.7 MILLION Source: (https://bit.ly/2OJ27IW) Further company coverage:

BRIEF-Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study For Oral Insulin

* ORAMED INITIATES ITS 90-DAY PIVOTAL DOSE-RANGING CLINICAL STUDY FOR ORAL INSULIN Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Oramed Pharmaceuticals' Unit Enters Clinical Research Organization Services Agreement With Integrium

* SAYS ON FEB 14, A UNIT ENTERED CLINICAL RESEARCH ORGANIZATION SERVICES AGREEMENT WITH INTEGRIUM EFFECTIVE AS OF NOV 1, 2017

BRIEF-Oramed receives approval for clinical study to treat NASH

* Oramed receives regulatory approval to conduct clinical study for treatment of NASH with its oral insulin capsule

BRIEF-Oramed pharmaceuticals ‍concludes its meeting with U.S. FDA regarding its oral insulin formulation​

* Concluded its meeting with U.S. FDA regarding ORMD-0801, company's novel oral insulin formulation

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up